UK: IPEC provides a quick and simple option in litigation

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

UK: IPEC provides a quick and simple option in litigation

The Intellectual Property Enterprise Court (IPEC) has an objective to provide quick and cost-effective IP litigation. It has proved to be popular.

A requirement for cheaper and quicker IP litigation was identified back in the 1980s. Small and medium-sized companies and individuals often found that traditional High Court litigation was expensive and time-consuming. Many were not prepared to enter litigation and take the risk of being liable for the other party's costs if they were to lose.

Small and medium businesses are the core users of IPEC. It has become recognised for high-quality decisions, and larger companies are now also attracted to using it for certain cases. Such cases have a limited number of issues and will not require extensive discovery or evidence. However, IPEC has become a victim of its own success and its diary has become fairly full.

One main advantage of using IPEC is the £50,000 ($70,000) limit on the costs which a winning party can claim from the losing party. This does not stop either party, but it does mean that one with a limited budget can afford to try, without fearing exorbitant costs if they lose.

There is a cap on damages as well; IPEC can only award damages of up to £500,000 ($698,000). However, a damages award may not be the main aim of a litigant. In many IP disputes a successful outcome is a full injunction which prevents a competitor from selling a competing product or process.

It is very important to prepare an IPEC case thoroughly from the outset. IPEC does not look kindly on speculative cases; all the issues and arguments must be presented at the start. Each party needs to focus on a few key points. For example, only a limited number of patent claims will be considered for infringement or validity. There simply is not the time to consider each claim in a lengthy patent.

Trial is often only a day or two at most, providing very limited time for cross-examination and disclosure. It pays to be extremely well-prepared and succinct in arguments. It can be an extremely useful forum for settling reasonably straightforward cases quickly.

Chapman

Helga Chapman

Chapman IP

Kings Park House, 22 Kings Park Road

Southampton SO15 2AT

United Kingdom

Tel: +44 (0) 23 8000 2022  

info@chapmanip.com  

www.chapmanip.com

more from across site and SHARED ros bottom lb

More from across our site

Evan Lazerowitz, attorney in Robinson + Cole’s bankruptcy and reorganisation group, offers key takeaways for IP interested parties in bankruptcy and insolvency proceedings
While the UK sees heavy IP rankings movement, Germany’s new tiered UPC table signals a shift from early adoption to market maturity
In an exclusive interview, Bernard Ledeboer reveals how a Consolid-backed group of firms wants to expand across Europe, invest in AI and centralise operations to compete at the top tier
Not all private equity firms are the same, so leaders at four externally backed IP firms came together to discuss the frameworks they followed and how they ensured a cultural fit
Top-tier German and Spanish firms are among the advisers on a Europe-wide copyright and licensing tussle concerning the design of the track circuit in Madrid
Partners Alex Wilson and Andreas Kramer say bigger law firm rivals don’t necessarily gain by having a wider jurisdictional reach
VO, which has offices in the Netherlands, Belgium and Germany, is the second European IP firm to secure external backing this week
The Bardehle Pagenberg attorneys-at-law discuss the firm’s Managing IP EMEA Awards 2026 success, Unified Patent Court litigation strategy, and evolving European patent trends
A patent battle between two legal tech companies and a loss for Elon Musk’s xAI against OpenAI were also among the top talking points
With drug prices a hot topic in the US, courts are seemingly more reluctant to prevent the entry of generics to the market
Gift this article